This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Serum biomarkers for prostate cancer	<p>Studies in mice and in patient samples identified serum glycoproteins that could be used for prostate cancer diagnosis and prognosis. In mice with prostate-specific deletion of <i>Pten</i> (<i>Mmac1; Tep1</i>), 126 glycoproteins were detectable in the serum and had altered abundance compared with those in wild-type tissue. In serum samples, a signature based on four of the glycoproteins distinguished between patients with prostate cancer and patients with benign prostatic hyperplasia (BPH). The signature had similar sensitivity and specificity to prostate-specific antigen (KLK3; PSA). Next steps include developing an ELISA-based test for the four markers.</p> <p>SciBX 4(9); doi:10.1038/scibx.2011.269 Published online March 3, 2011</p>	Patent application filed; licensed exclusively to ProteoMediX AG	<p>Cima, I. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Feb. 7, 2011; doi:10.1073/pnas.1013699108</p> <p>Contact: Wilhelm Krek, Swiss Federal Institute of Technology Zurich (ETHZ), Zurich, Switzerland e-mail: wilhelm.krek@cell.biol.ethz.ch</p> <p>Contact: Ruedi Aebersold, same affiliation as above e-mail: aebersold@imsb.biol.ethz.ch</p> <p>Contact: Holger Moch, University Hospital Zurich, Zurich, Switzerland e-mail: holger.moch@usz.ch</p> <p>Contact: Silke Gillessen, Cantonal Hospital St. Gallen, St. Gallen, Switzerland e-mail: silke.gillessen@kssg.ch</p>